

Product Datasheet

FATP5/SLC27A5 Antibody - BSA Free NBP1-89267

Unit Size: 0.1 ml

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 2

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP1-89267

Updated 3/4/2026 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP1-89267



NBP1-89267

FATP5/SLC27A5 Antibody - BSA Free


Product Information	
Unit Size	0.1 ml
Concentration	Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Affinity purified
Buffer	PBS (pH 7.2) and 40% Glycerol

Product Description	
Host	Rabbit
Gene ID	10998
Gene Symbol	SLC27A5
Species	Human
Reactivity Notes	Immunogen displays the following percentage of sequence identity for non-tested species: Rat (80%). Human reactivity reported in scientific literature (PMID: 23415802).
Immunogen	This antibody was developed against Recombinant Protein corresponding to amino acids: RVLVVDLRESLEEILPKLQAENIRCFYLSHTSPTPGVVGALGAALDAAPSHPV PADLRAGITWRSPALFIYTS GTTGLPKPAILTHERVLQMSKMLSLSGATADDVV YTVLPLYHVMGLVVG


Product Application Details	
Applications	Western Blot, Immunohistochemistry-Paraffin, Immunohistochemistry
Recommended Dilutions	Western Blot 0.04-0.4 ug/ml, Immunohistochemistry 1:200 - 1:500, Immunohistochemistry-Paraffin 1:200 - 1:500
Application Notes	For IHC-Paraffin, HIER pH 6 retrieval is recommended.

Images


Immunohistochemistry-Paraffin: FATP5/SLC27A5 Antibody [NBP1-89267] - Staining in human liver and pancreas tissues using anti-SLC27A5 antibody. Corresponding SLC27A5 RNA-seq data are presented for the same tissues.




Western Blot: FATP5/SLC27A5 Antibody [NBP1-89267] - Analysis in human liver tissue.




Immunohistochemistry-Paraffin: FATP5/SLC27A5 Antibody [NBP1-89267] - Staining of human liver shows high expression.




Immunohistochemistry-Paraffin: FATP5/SLC27A5 Antibody [NBP1-89267] - Staining of human pancreas shows low expression as expected.




SLC27A5 expression is downregulated in the sorafenib-resistant hepatocellular carcinoma cells. A Schematic diagram of the construction of the sorafenib-resistant cells. B The IC₅₀ values of sorafenib-sensitive and sorafenib-resistant SK-Hep1 and HepG2 cells that were incubated with sorafenib in a concentration gradient manner. C, D The mRNA (C) and protein (D) expression of SLC27A5 in sorafenib-sensitive and sorafenib-resistant HCC cells. SR sorafenib resistant. All data are presented as mean \pm SD (n = 3). Statistical significance was calculated using two-tailed unpaired Student's t-test. *p < 0.05, **p < 0.01, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36635256>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




SLC27A5 depletion activated NRF2/GSR axis in HCC. A, B Representative mRNA levels of NRF2 downstream gene expression in SLC27A5-overexpression (A) and SLC27A5-KO (B) cells under treatment of sorafenib. C Relative mRNA levels of GSR in sorafenib-sensitive (n = 3) and sorafenib-resistant (n = 3) human liver tumors. D Correlation analysis of the mRNA levels of SLC27A5 and GSR in the liver by Spearman. E Histochemical staining for SLC27A5 and GSR in HCC tissues and adjacent non-cancerous tissues. Scale bar: 50 μ m. F Relative protein expression of NRF2 and GSR were detected by western blotting in SLC27A5-overexpression SK-Hep1 cultured with sorafenib (10 μ M for 24 h) alone or co-treatment with tBHQ (100 μ M for 3 h). G Relative protein expression of NRF2 and GSR were detected by western blotting in SLC27A5-KO HepG2 cultured with sorafenib alone or co-treatment with brusatol (40 nM for 24 h). H Kaplan–Meier survival curve analysis based on the expression of SLC27A5 and GSR in the liver tumor. I, J The activity of GSR was determined by the GSR activity kit in SLC27A5-overexpression SK-Hep1 (I) and SLC27A5-KO HepG2 (J). TPM transcripts per million, tBHQ tertiary butylhydroquinone, Bru brusatol. Data shown are mean \pm SD (n = 3). Statistical significance was calculated using two-tailed unpaired Student's t-test and one-way ANOVA test. *p < 0.05, **p < 0.01 ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36635256>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




SLC27A5 depletion activated NRF2/GSR axis in HCC. A, B Representative mRNA levels of NRF2 downstream gene expression in SLC27A5-overexpression (A) and SLC27A5-KO (B) cells under treatment of sorafenib. C Relative mRNA levels of GSR in sorafenib-sensitive (n = 3) and sorafenib-resistant (n = 3) human liver tumors. D Correlation analysis of the mRNA levels of SLC27A5 and GSR in the liver by Spearman. E Histochemical staining for SLC27A5 and GSR in HCC tissues and adjacent non-cancerous tissues. Scale bar: 50 μ m. F Relative protein expression of NRF2 and GSR were detected by western blotting in SLC27A5-overexpression SK-Hep1 cultured with sorafenib (10 μ M for 24 h) alone or co-treatment with tBHQ (100 μ M for 3 h). G Relative protein expression of NRF2 and GSR were detected by western blotting in SLC27A5-KO HepG2 cultured with sorafenib alone or co-treatment with brusatol (40 nM for 24 h). H Kaplan–Meier survival curve analysis based on the expression of SLC27A5 and GSR in the liver tumor. I, J The activity of GSR was determined by the GSR activity kit in SLC27A5-overexpression SK-Hep1 (I) and SLC27A5-KO HepG2 (J). TPM transcripts per million, tBHQ tertiary butylhydroquinone, Bru brusatol. Data shown are mean \pm SD (n = 3). Statistical significance was calculated using two-tailed unpaired Student's t-test and one-way ANOVA test. *p < 0.05, **p < 0.01 ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36635256>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




BCNU enhances the curative effect of sorafenib in vivo by inducing ferroptosis. A Establishment protocol for the evaluation of tumor growth and resistance of human HepG2-parental and HepG2-SR tumor xenografts in BALB/C nude mice following therapy with sorafenib and BCNU alone or both. B Gross images of the HepG2-derived xenografts in orthotopic implantation model. C, D Analysis of liver/body weight ratio (C) (n = 6) and tumor numbers (D) (n = 6). E, F Relative protein expression of SLC27A5 and GSR in the tumor tissues was assayed by immunohistochemistry (E) and immunoblotting (F). Scale bar: 50 μ m. G–I The level of GSR activity (G) (n = 6), GSH/GSSG ratio (H) (n = 6), and ROS (I) (n = 6) were assayed in tumor tissues. Scale bar: 10 μ m. Data shown are mean \pm SD. Statistical significance was calculated using one-way ANOVA test. *p < 0.05, **p < 0.01, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36635256>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



BCNU enhances the curative effect of sorafenib in vivo by inducing ferroptosis. A Establishment protocol for the evaluation of tumor growth and resistance of human HepG2-parental and HepG2-SR tumor xenografts in BALB/C nude mice following therapy with sorafenib and BCNU alone or both. B Gross images of the HepG2-derived xenografts in orthotopic implantation model. C, D Analysis of liver/body weight ratio (C) (n = 6) and tumor numbers (D) (n = 6). E, F Relative protein expression of SLC27A5 and GSR in the tumor tissues was assayed by immunohistochemistry (E) and immunoblotting (F). Scale bar: 50 μ m. G–I The level of GSR activity (G) (n = 6), GSH/GSSG ratio (H) (n = 6), and ROS (I) (n = 6) were assayed in tumor tissues. Scale bar: 10 μ m. Data shown are mean \pm SD. Statistical significance was calculated using one-way ANOVA test. *p < 0.05, **p < 0.01, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36635256>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



SLC27A5 depletion activated NRF2/GSR axis in HCC. A, B Representative mRNA levels of NRF2 downstream gene expression in SLC27A5-overexpression (A) and SLC27A5-KO (B) cells under treatment of sorafenib. C Relative mRNA levels of GSR in sorafenib-sensitive (n = 3) and sorafenib-resistant (n = 3) human liver tumors. D Correlation analysis of the mRNA levels of SLC27A5 and GSR in the liver by Spearman. E Histochemical staining for SLC27A5 and GSR in HCC tissues and adjacent non-cancerous tissues. Scale bar: 50 μ m. F Relative protein expression of NRF2 and GSR were detected by western blotting in SLC27A5-overexpression SK-Hep1 cultured with sorafenib (10 μ M for 24 h) alone or co-treatment with tBHQ (100 μ M for 3 h). G Relative protein expression of NRF2 and GSR were detected by western blotting in SLC27A5-KO HepG2 cultured with sorafenib alone or co-treatment with brusatol (40 nM for 24 h). H Kaplan–Meier survival curve analysis based on the expression of SLC27A5 and GSR in the liver tumor. I, J The activity of GSR was determined by the GSR activity kit in SLC27A5-overexpression SK-Hep1 (I) and SLC27A5-KO HepG2 (J). TPM transcripts per million, tBHQ tertiary butylhydroquinone, Bru brusatol. Data shown are mean \pm SD (n = 3). Statistical significance was calculated using two-tailed unpaired Student's t-test and one-way ANOVA test. *p < 0.05, **p < 0.01, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36635256>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Setchell KD, Heubi JE, Shah S et al. GENETIC DEFECTS IN BILE ACID CONJUGATION CAUSE FAT-SOLUBLE VITAMIN DEFICIENCY. *Gastroenterology* 2013-05-01 [PMID: 23415802] (IF/IHC, Human)

HadZic N, Bull LN, Clayton PT et al. Diagnosis in bile acid-CoA: amino acid N-acyltransferase deficiency. *World J Gastroenterol* 2012-07-01 [PMID: 22783059]





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP1-89267

NBP1-89267PEP	FATP5/SLC27A5 Recombinant Protein Antigen
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP1-89267

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

